GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 Notes to the Consolidated Financial Statements for the year ended March 31, 2022 242 The gross movement in the current tax asset/(liability) for the year ended March 31, 2022 and March 31, 2021 is as follows: ( ` in lakhs ) As at March 31, 2022 March 31, 2021 Net current income tax asset/(liability) at the beginning 182,77.75 148,42.03 Income tax Paid 620,36.28 229,66.96 Refund received during the year (99,83.36) (11,01.07) Current Income Tax Expense (613,97.09) (184,30.17) Tax Adjustment of earlier years (187,93.53) - Net current income tax asset/(liability) at the end (98,59.95) 182,77.75 (f) Unused tax losses on which no deferred tax asset has been recognised ( ` in lakhs ) Nature of Loss As at March 31, 2022 As at March 31, 2021 Base Amount Expiry date Base Amount Expiry date Capital Loss 894,42.25 FY 2029-30 - - Note 48 : Leases Future contractual charges on leases: The table below provides details regarding the contractual maturities of lease liabilities as at March 31, 2022 on an undiscounted basis: ( ` in lakhs ) 0-1 years 1-2 years 2-3 years 3-4 years 4-5 years Above 5 years 11,89.98 5,16.96 2,34.32 66.39 - - Right of use asset ( ` in lakhs ) Buildings Balance as on April 1, 2021 31,26.43 Additions 1,06.74 Less: Depreciation (14,75.69) Balance as on March 31, 2022 17,57.48 Other financial lease liabilities ( ` in lakhs ) Buildings Lease liabilities recognised as at April 1, 2021 34,60.26 Additions 1,02.75 Add: Interest accrued during the period 1,73.70 Less: Payments (17,29.06) Lease liabilities recognised as at March 31, 2022 20,07.65 Current lease liabilities 12,45.30 Non current lease liabilities 7,62.35 Borrowing rate - discounting rate used by the Group The lessee’s weighted average incremental borrowing rate applied to the lease liabilities was 4.23% to 7.59%.